|
Dr Frank Mathias, Ph.D, Chief Executive Officer
Dr Frank Mathias has been Chief Executive Officer since April 2009, and was previously the Board Member responsible for Marketing and Business Development. Dr Mathias possesses around 20
years of experience in pharmaceutical marketing at management level with international companies, most recently with Amgen. Dr Mathias studied pharmacy at Paris VI University, earning his
PhD in 1991. He began his industrial career in 1988 as International Product Manager with Hoechst AG in Frankfurt and in 1990 joined Albert-Roussel Pharma GmbH in Wiesbaden, first as a
Pharmaceuticals Officer then as a Product Group Manager, finishing as Deputy Head of Marketing. In 1995, Dr Mathias launched the Anti-Infective Marketing Department at Hoechst Pharma in
Frankfurt before moving to Servier Deutschland GmbH in Munich as Head of Marketing and thereafter as General Manager. In 2002, he joined Amgen GmbH, Munich, as Head of Marketing and took
over as General Manager from 2003–2007.
|
 |
Arnd Christ, Chief Financial Officer
Arnd Christ has 15 years of international experience in business finance and management as well as mergers and acquisitions. During his tenure as Chief Financial Officer at the biotech
company NovImmune SA, Geneva, Switzerland, the company successfully closed one of the largest private financing rounds (CHF 62.5 million) in the European biotech industry. Prior to joining
NovImmune, Mr. Christ held the position as Chief Financial Officer of Probiodrug AG, Halle, for 5 years, where he was responsible for several fund raising rounds as well as for the
successful closing of a major asset sale to OSI Pharmaceuticals Inc. Before joining Probiodrug AG, Arnd Christ was finance manager at several subsidiaries of the Hoechst Group in Germany
and UK. Arnd Christ studied at the Julius-Maximilians-Universität in Würzburg and holds a degree in business administration.
|
